All subjects will receive maraviroc 300mg orally twice a day for 6 weeks ( DrugBank: Maraviroc )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 84 | Sarcoidosis | 1 |
84. Sarcoidosis
Clinical trials : 149 / Drugs : 227 - (DrugBank : 81) / Drug target genes : 82 - Drug target pathways : 167
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02134717 (ClinicalTrials.gov) | January 2014 | 30/4/2014 | Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes | An Interventional Study of the Effect of CCR5 Inhibition With Maraviroc on Immune Cells in the the Lung and in Peripheral Blood of Patients With Sarcoidosis | Sarcoidosis | Drug: all subjects will receive maraviroc 300mg orally twice a day for 6 weeks;Procedure: Bronchoscopy with bronchoalveolar lavage;Procedure: venipunctures;Procedure: Skin biopsy | Kevin F. Gibson | University of Pittsburgh | Terminated | 18 Years | 80 Years | All | 3 | N/A | United States |